PAPPA2‐Mut presented the lowest risk of progression or death in both sets (NSCLC: HR, 0.28 [95% CI, 0.04–0.53]; p < 0.001; SKCM set: HR, 0.49 [95% CI, 0.31–0.78]; p = 0.003). This evidence concerns the gene PAPPA2 and non-small cell lung carcinoma.